The Rate of Drug-Resistant Tuberculosis in Korean Children and Adolescents Since 2007.
10.3346/jkms.2017.32.6.954
- Author:
Hyun Jung KIM
1
;
Hyung Ho YOON
;
Byung Wook EUN
;
Youngmin AHN
;
Sungweon RYOO
;
Hee Jin KIM
Author Information
1. Department of Pediatrics, Eulji General Hospital, Eulji University, Seoul, Korea. aym3216@eulji.ac.kr
- Publication Type:Original Article
- Keywords:
Adolescent;
Child;
Multidrug-Resistant;
Pediatric;
Tuberculosis
- MeSH:
Adolescent*;
Child*;
Drug Resistance;
Ethambutol;
Humans;
Incidence;
Isoniazid;
Mycobacterium tuberculosis;
Pyrazinamide;
Rifampin;
Tuberculosis;
Tuberculosis, Multidrug-Resistant*
- From:Journal of Korean Medical Science
2017;32(6):954-960
- CountryRepublic of Korea
- Language:English
-
Abstract:
The incidence of drug-resistant tuberculosis (DR-TB) in pediatric populations is a critical indicator of national TB management and treatment strategies. Limited data exist regarding the rate of pediatric DR-TB. In this study, we aimed to analyze the status of DR-TB in Korean children from 2007 to 2013. We analyzed specimens submitted to the Korean Institute of Tuberculosis using Mycobacterium tuberculosis culture and drug susceptibility tests (DSTs) from January 2007 through December 2013. Specimens from patients ≤ 19 years of age were included. Among the 2,690 cases, 297 cases were excluded because of insufficient data, leaving 2,393 cases for the final analysis. In total, resistance to one or more TB drugs was 13.5%. The resistance rates of each of the drugs were as follows: isoniazid (INH) 10.2%, rifampin (RFP) 5.1%, ethambutol (EMB) 3.7%, and pyrazinamide (PZA) 3.1%. The resistance rate of multidrug-resistant TB (MDR-TB) was 4.2%, and that of extensively drug-resistant TB (XDR-TB) was 0.8%. The overall drug resistance rate demonstrated significant increase throughout the study period (P < 0.001) but showed no significant difference compared to previous study from 1999 to 2007. The drug resistance rate of PZA in ≤ 15 years of age group was significantly greater than that of > 15 years (P < 0.001). The drug resistance rate has increased throughout the study period.
